• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白细胞介素-21 工程通过 CEBPD 增强 NK 细胞对神经胶质瘤的活性。

Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD.

机构信息

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.

出版信息

Cancer Cell. 2024 Aug 12;42(8):1450-1466.e11. doi: 10.1016/j.ccell.2024.07.007.

DOI:10.1016/j.ccell.2024.07.007
PMID:39137729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11370652/
Abstract

Glioblastoma (GBM) is an aggressive brain cancer with limited therapeutic options. Natural killer (NK) cells are innate immune cells with strong anti-tumor activity and may offer a promising treatment strategy for GBM. We compared the anti-GBM activity of NK cells engineered to express interleukin (IL)-15 or IL-21. Using multiple in vivo models, IL-21 NK cells were superior to IL-15 NK cells both in terms of safety and long-term anti-tumor activity, with locoregionally administered IL-15 NK cells proving toxic and ineffective at tumor control. IL-21 NK cells displayed a unique chromatin accessibility signature, with CCAAT/enhancer-binding proteins (C/EBP), especially CEBPD, serving as key transcription factors regulating their enhanced function. Deletion of CEBPD resulted in loss of IL-21 NK cell potency while its overexpression increased NK cell long-term cytotoxicity and metabolic fitness. These results suggest that IL-21, through C/EBP transcription factors, drives epigenetic reprogramming of NK cells, enhancing their anti-tumor efficacy against GBM.

摘要

胶质母细胞瘤(GBM)是一种侵袭性脑癌,治疗选择有限。自然杀伤(NK)细胞是先天免疫细胞,具有强大的抗肿瘤活性,可能为 GBM 提供一种有前途的治疗策略。我们比较了表达白细胞介素(IL)-15 或 IL-21 的 NK 细胞的抗 GBM 活性。使用多种体内模型,IL-21 NK 细胞在安全性和长期抗肿瘤活性方面均优于 IL-15 NK 细胞,局部给予的 IL-15 NK 细胞具有毒性且无法控制肿瘤。IL-21 NK 细胞显示出独特的染色质可及性特征,CCAAT/增强子结合蛋白(C/EBP),特别是 CEBPD,作为关键转录因子调节其增强功能。CEBPD 的缺失导致 IL-21 NK 细胞效力丧失,而过表达增加了 NK 细胞的长期细胞毒性和代谢适应性。这些结果表明,IL-21 通过 C/EBP 转录因子驱动 NK 细胞的表观遗传重编程,增强其对 GBM 的抗肿瘤功效。

相似文献

1
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD.白细胞介素-21 工程通过 CEBPD 增强 NK 细胞对神经胶质瘤的活性。
Cancer Cell. 2024 Aug 12;42(8):1450-1466.e11. doi: 10.1016/j.ccell.2024.07.007.
2
Novel fusion superkine, , enhances immunotherapy of brain cancer.新型融合超细胞因子 增强脑癌免疫治疗效果
J Immunother Cancer. 2025 Jun 22;13(6):e011198. doi: 10.1136/jitc-2024-011198.
3
Human iPSC-derived NK cells armed with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complex enhance anti-solid tumor activity.携带CCL19、CCR2B、高亲和力CD16、IL-15和NKG2D复合物的人诱导多能干细胞衍生的自然杀伤细胞增强抗实体瘤活性。
Stem Cell Res Ther. 2025 Jul 15;16(1):373. doi: 10.1186/s13287-025-04461-9.
4
Dual IL-2/IL-21 priming augments the anti-tumor function of CD16V-CAR/TRAIL-engineered NK cells in combination with monoclonal antibodies.双重IL-2/IL-21预刺激增强了CD16V-CAR/TRAIL工程化自然杀伤细胞与单克隆抗体联合使用时的抗肿瘤功能。
Biomed Pharmacother. 2025 Aug;189:118289. doi: 10.1016/j.biopha.2025.118289. Epub 2025 Jun 24.
5
Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer.靶向B7-H3的新型三特异性杀伤细胞衔接器增强自然杀伤细胞对头颈部癌的抗肿瘤活性。
J Immunother Cancer. 2025 Jul 23;13(7):e011370. doi: 10.1136/jitc-2024-011370.
6
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells.一种 ADAM17 功能阻断抗体增强了 IL-15 介导的 NK 细胞激活和增殖,涉及 CD16A、CD137 和辅助细胞。
J Immunother Cancer. 2024 Jul 24;12(7):e008959. doi: 10.1136/jitc-2024-008959.
7
Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages.阻断整合素α5(ITGA5)可通过重塑肿瘤相关巨噬细胞增强抗程序性死亡蛋白1(PD-1)疗法对胶质母细胞瘤的疗效。
Cancer Commun (Lond). 2025 Mar 14. doi: 10.1002/cac2.70016.
8
IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.IL-13Rα2/TGF-β 双特异性 CAR-T 细胞可克服 TGF-β 介导的免疫抑制,增强胶质母细胞瘤的抗肿瘤反应。
Neuro Oncol. 2024 Oct 3;26(10):1850-1866. doi: 10.1093/neuonc/noae126.
9
New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.从单细胞 lncRNA 表达分析中获得胶质母细胞瘤精准治疗的新见解。
J Cancer Res Clin Oncol. 2021 Jul;147(7):1881-1895. doi: 10.1007/s00432-021-03584-9. Epub 2021 Mar 11.
10
PM21-particle stimulation augmented with cytokines enhances NK cell expansion and confers memory-like characteristics with enhanced survival.PM21 颗粒刺激联合细胞因子增强 NK 细胞扩增,并赋予其具有增强存活能力的记忆样特征。
Front Immunol. 2024 Apr 22;15:1383281. doi: 10.3389/fimmu.2024.1383281. eCollection 2024.

引用本文的文献

1
Next-generation multiplex-edited CAR-NK cells: more edits, more power?下一代多重编辑的嵌合抗原受体自然杀伤细胞(CAR-NK细胞):更多编辑,更强效力?
J Immunother Cancer. 2025 Sep 15;13(9):e012841. doi: 10.1136/jitc-2025-012841.
2
Unraveling the Clinical Landscape of RNA Modification Regulators with Multi-Omics Insights in Pan-Cancer.通过多组学洞察揭示泛癌中RNA修饰调控因子的临床格局
Cancers (Basel). 2025 Aug 19;17(16):2695. doi: 10.3390/cancers17162695.
3
Loss of YTHDF2 enhances Th9 programming and CAR-Th9 cell antitumor efficacy.YTHDF2的缺失增强了Th9细胞的分化编程及CAR-Th9细胞的抗肿瘤功效。
Nat Immunol. 2025 Aug 18. doi: 10.1038/s41590-025-02235-2.
4
Harnessing innate immunity against glioblastoma microenvironment.利用针对胶质母细胞瘤微环境的先天免疫。
Front Immunol. 2025 Jul 25;16:1648601. doi: 10.3389/fimmu.2025.1648601. eCollection 2025.
5
Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control.组成性白细胞介素-7信号通路促进实体瘤微环境中嵌合抗原受体自然杀伤(CAR-NK)细胞的存活,但损害肿瘤控制。
J Immunother Cancer. 2025 Jul 23;13(7):e010672. doi: 10.1136/jitc-2024-010672.
6
Cancer stem cells: Bridging microenvironmental interactions and clinical therapy.癌症干细胞:连接微环境相互作用与临床治疗
Clin Transl Med. 2025 Jul;15(7):e70406. doi: 10.1002/ctm2.70406.
7
Prospects and applications of NK therapy in the treatment of gliomas (Review).NK细胞疗法在胶质瘤治疗中的前景与应用(综述)
Oncol Rep. 2025 Aug;54(2). doi: 10.3892/or.2025.8921. Epub 2025 Jun 6.
8
CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells.CREM是自然杀伤细胞中CAR和IL-15信号传导的一个调节检查点。
Nature. 2025 Jun 4. doi: 10.1038/s41586-025-09087-8.
9
Adjusting the scope of natural killer cells in cancer therapy.调整自然杀伤细胞在癌症治疗中的作用范围。
Cell Mol Immunol. 2025 May 23. doi: 10.1038/s41423-025-01297-4.
10
Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy.聚焦细胞因子:自然杀伤细胞过继性细胞癌症免疫疗法中的白细胞介素-2和白细胞介素-15
Immune Netw. 2025 Apr 9;25(2):e17. doi: 10.4110/in.2025.25.e17. eCollection 2025 Apr.

本文引用的文献

1
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 B cell tumors: a phase 1/2 trial.同种异体 CD19 特异性 CAR-NK 细胞治疗 CD19 B 细胞肿瘤的安全性、有效性和反应决定因素:一项 1/2 期试验。
Nat Med. 2024 Mar;30(3):772-784. doi: 10.1038/s41591-023-02785-8. Epub 2024 Jan 18.
2
IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development.IKAROS 和 AIOLOS 直接调节 AP-1 转录复合物,是 NK 细胞发育所必需的。
Nat Immunol. 2024 Feb;25(2):240-255. doi: 10.1038/s41590-023-01718-4. Epub 2024 Jan 5.
3
Dictionary of immune responses to cytokines at single-cell resolution.细胞因子免疫反应词典:单细胞解析
Nature. 2024 Jan;625(7994):377-384. doi: 10.1038/s41586-023-06816-9. Epub 2023 Dec 6.
4
Microglial morphometric analysis: so many options, so little consistency.小胶质细胞形态计量分析:选择众多,一致性却很差。
Front Neuroinform. 2023 Aug 10;17:1211188. doi: 10.3389/fninf.2023.1211188. eCollection 2023.
5
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.在复发性胶质母细胞瘤患者中,经 HER2 靶向嵌合抗原受体工程化的自然杀伤细胞颅内注射。
Neuro Oncol. 2023 Nov 2;25(11):2058-2071. doi: 10.1093/neuonc/noad087.
6
The application of Interleukin-2 family cytokines in tumor immunotherapy research.白细胞介素-2 家族细胞因子在肿瘤免疫治疗研究中的应用。
Front Immunol. 2023 Mar 2;14:1090311. doi: 10.3389/fimmu.2023.1090311. eCollection 2023.
7
Clonal expansion and epigenetic inheritance of long-lasting NK cell memory.克隆扩增和 NK 细胞记忆的表观遗传遗传。
Nat Immunol. 2022 Nov;23(11):1551-1563. doi: 10.1038/s41590-022-01327-7. Epub 2022 Oct 26.
8
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.基于 KIR 的抑制性 CAR 可克服 CAR-NK 细胞 trogocytosis 介导的自相残杀和肿瘤逃逸。
Nat Med. 2022 Oct;28(10):2133-2144. doi: 10.1038/s41591-022-02003-x. Epub 2022 Sep 29.
9
Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy.利用 IL-15 信号转导增强 NK 细胞介导的癌症免疫治疗。
Trends Immunol. 2022 Oct;43(10):833-847. doi: 10.1016/j.it.2022.08.004. Epub 2022 Sep 1.
10
Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion.激活和抑制性受体的平衡参与减轻了人 NK 细胞衰竭。
JCI Insight. 2022 Aug 8;7(15):e150079. doi: 10.1172/jci.insight.150079.